Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19297124 | 0.83 | MAPT (0.43) | GPR55MAPTCRHBPCRHR2RECQL | |
| SCHEMBL11189590 | 0.75 | CES1 (0.36) | PARP1PSMB5 | |
| SCHEMBL19297010 | 0.75 | MAPT (0.44) | GPR55MAPTCRHBPCRHR2RECQL | |
| SCHEMBL3254152 | 0.73 | GPR55 (0.41) | GPR55MAPTCRHBPCRHR2RECQL | |
| SCHEMBL14849268 | 0.72 | NUAK1 (0.39) | GPR55MAPTCRHBPCRHR2CNR2 | |
| SCHEMBL19297005 | 0.70 | MAPT (0.43) | MAPTCRHBPCRHR2 | |
| SCHEMBL19297001 | 0.70 | GPR55 (0.36) | GPR55MAPTCRHBPCRHR2RECQL | |
| SCHEMBL19297004 | 0.69 | MAPT (0.39) | GPR55MAPTCRHBPCRHR2RECQL | |
| SCHEMBL9606822 | 0.69 | MAOA (0.41) | GPR55MAPTCRHBPCRHR2CNR2 | |
| SCHEMBL6127869 | 0.68 | MAPT (0.41) | GPR55MAPTCRHBPCRHR2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954215-B2 | Compounds as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-23 | — | — | US | disclosed |
| EP-3555065-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-20200071298-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2018111803-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954215-B2 | Compounds as modulators of ROR gamma | RORB, RORC, RORA | GPR55 140/4885MAPT 2717/4885CRHBP 1042/4885 |
| US-20200071298-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORC, RORB, RORA | GPR55 167/4885MAPT 2077/4885CRHBP 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.